Imfinzi Side Effects

Generic Name: durvalumab

Medically reviewed by Drugs.com. Last updated on Sep 21, 2020.

Consumer
Professional
FAQ

Note: This document contains side effect information about durvalumab. Some of the dosage forms listed on this page may not apply to the brand name Imfinzi.

For the Consumer

Applies to durvalumab: intravenous solution

Side effects requiring immediate medical attention

Along with its needed effects, durvalumab (the active ingredient contained in Imfinzi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking durvalumab:

More common

Bladder pain
bloating or swelling of the face, arms, hands, lower legs, or feet
bloody or cloudy urine
depressed mood
difficult, burning, or painful urination
difficulty having a bowel movement
dry skin and hair
feeling cold
fever
frequent urge to urinate
hair loss
hoarseness or husky voice
lower back or side pain
muscle cramps and stiffness
pain
rapid weight gain
slowed heartbeat
stomach cramps
tenderness
tingling of the hands or feet
unusual tiredness or weakness
unusual weight gain or loss
watery or bloody diarrhea

Less common

Chest pain
chills
cough
dark urine
difficult breathing
general feeling of discomfort or illness
general tiredness and weakness
light-colored stools
nausea
nervousness
sensitivity to heat
sweating
thickening of bronchial secretions
trouble sleeping
upper right abdominal or stomach pain
vomiting
weight loss
yellow eyes and skin

Less common or rare

Back, leg, or stomach pains
black, tarry stools
bleeding gums
bloody nose
blurred vision or other changes in vision
chest tightness
eye redness, irritation, or pain
general body swelling
headache
heavier menstrual periods
loss of appetite
nosebleeds
pale skin
pinpoint red spots on the skin
redness of the eye
sensitivity of the eye to light
skin rash
sore throat
stiff neck or back
tearing
unusual bleeding or bruising

Rare

Dizziness
drowsiness
fainting

Side effects not requiring immediate medical attention

Some side effects of durvalumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Decreased appetite
muscle or joint pain

For Healthcare Professionals

Applies to durvalumab: intravenous solution

Endocrine

Common (1% to 10%): Immune-mediated endocrinopathies (e.g., hypothyroidism, hyperthyroidism, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis/hypopituitarism)^[Ref]

Dermatologic

Very common (10% or more): Rash (dermatitis, dermatitis acneiform, dermatitis psoriasiform, psoriasis, rash maculopapular, rash pruritic, rash papular, rash pustular, skin toxicity, eczema, erythema, erythema multiforme, rash erythematous, acne, lichen planus) (11%)^[Ref]

Cardiovascular

Uncommon (0.1% to 1%): Immune-related myocarditis^[Ref]

Hematologic

Very common (10% or more): Lymphopenia (11%)

Common (1% to 10%): Anemia^[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (e.g., cystitis, candiduria, urosepsis) (15%)^[Ref]

Gastrointestinal

Very common (10% or more): Constipation (21%), nausea (16%), abdominal pain (upper, lower, flank) (14%), diarrhea/colitis (13%)

Common (1% to 10%): Dehydration

Frequency not reported: Immune-mediated colitis^[Ref]

Hepatic

Common (1% to 10%): Liver injury, immune-mediated hepatitis

Uncommon (0.1% to 1%): Increased ASO, increased ALT, hyperbilirubinemia

Frequency not reported: Immune-mediated hepatitis^[Ref]

Metabolic

Very common (10% or more): Decreased appetite/hypophagia (19%), hyponatremia (12%)

Common (1% to 10%): Deterioration of general physical health, increased alkaline phosphatase, hypermagnesemia, hypercalcemia, hyperglycemia, neutropenia, hyperkalemia, hypoalbuminemia^[Ref]

Local

Common (1% to 10%): Infusion-related reactions^[Ref]

Immunologic

Common (1% to 10%): Infections (e.g., sepsis, necrotizing fasciitis, osteomyelitis)^[Ref]

Ocular

Uncommon (0.1% to 1%): Uveitis and keratitis^[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., back pain, musculoskeletal chest pain, musculoskeletal pain and discomfort, myalgia, neck pain) (24%)^[Ref]

Nervous system

Common (1% to 10%): Pyrexia/tumor associated fever

Uncommon (0.1% to 1%): Immune-related aseptic meningitis^[Ref]

Other

Very common (10% or more): Fatigue (e.g., asthenia, lethargy, malaise) (39%), peripheral edema (e.g., edema, localized edema, edema peripheral, lymphedema, peripheral swelling, scrotal edema, scrotal swelling) (15%), pyrexia/tumor associated fever (14%)

Common (1% to 10%): Embryofetal toxicity^[Ref]